Cycloplegics

Clinical Ocular Pharmacology

Volumn , Issue , 2008, Pages 125-138

  Frazier, Marcela ^a   Jaanus, Siret D ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882493629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7576-5.50014-8     Document Type: Chapter

References (45)

1. Anicho UM, Cooper J, Feldman J, et al. A study of the clinical efficacy of Paremyd with and without dapiprazole in subjects with light and dark brown irides. Optom Vis Sci 1999, 76:94-101.
2. Applebaum MA, Jaanus SD Use of diagnostic pharmaceutical agents and incidence of adverse effects. Am J Optom Physiol Opt 1983, 60:384-388.
3. Binkhorst RD, Weinstein GW, Baretz RM, Clahane MS Psychotic reaction induced by cyclopentolate. Am J Ophthalmol 1963, 56:1243-1245.
4. Brown C, Hanna C Use of dilute drug solutions for routine cycloplegia and mydriasis. Am J Ophthalmol 1978, 86:820-824.
5. Brown JH Atropine, scopolamine and related antimuscarinic drugs. Goodman and Gilman's the pharmacological basis of therapeutics 1990, McGraw-Hill, New York, Chapter 8. A.G. Gilman, T.W. Rall, A.S. Nies (Eds.).
6. Brown MM, Brown GC, Spaeth GL Lack of side effects from topically administered 10% phenylephrine eyedrops. Arch Ophthalmol 1980, 98:487-489.
7. Chou A-C, Shih Y-F, Ho T-C, Lin LL-K The effectiveness of 0.5% atropine in controlling high myopia in children. J Ocul Pharmacol Ther 1997, 13:61-67.
8. Dillon JR, Tyhurst CW, Yolton RL The mydriatic effect of tropic-amide on light and dark irides. J Am Optom Assoc 1977, 48:653-658.
9. Egashira AM, Kish LL, Twelker JD, et al. Comparison of cyclopen-tolate versus tropicamide cycloplegia in children. Optom Vis Sci 1993, 70:1019-1026.
10. Eggers HM Toxicity of drugs used in diagnosis and treatment of strabismus. Ocular therapeutics 1980, 115-122. Masson, New York, Chapter 15. D.B. Srinivasan (Ed.).
11. Feddersen IM Beitrag zur Atropinvergiftung. Inaug Dissert Berlin; Francke O. 1884, as cited by Marron J. Cycloplegia and mydriasis by use of atropine, scopolamine and homatropine-paredrine. Arch Ophthalmol 1940, 23:340-350.
12. Fitzgerald DA, Hanson RM, West C, et al. Seizures associated with 1% cyclopentolate eyedrops. J Paediatr Child Health 1990, 26:106-107.
13. Gambill HD, Ogle KN, Kearns TP Mydriatic effect of four drugs determined with pupillograph. Arch Ophthalmol 1967, 77:740-746.
14. Gettes BC Tropicamide: comparative mydriatic effects. Am J Ophthalmol 1963, 55:84-87.
15. Gettes BD, Leopold IH Evaluation of five new cycloplegic drugs. Arch Ophthalmol 1953, 49:24-27.
16. Gil DW, Krauss HA, Bogardus AM, Wolde-Mussie E Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest Ophthalmol Vis Sci 1997, 38:1434-1442.
17. Huang F, Wu WM, Ji F, et al. Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. Pharmazie 2002, 57:115-121.
18. Iijima A, Haida M, Ishikawa N, et al. Re-evaluation of tropicamide in the pupillary response test for Alzheimer's disease. Neurobiol Aging 2003, 24:789-796.
19. Jaanus SD Pharmacologic aspects of aging. Vision and aging 1993, ButterworthHeinemann, Boston, Chapter 5. A.A. Rosenbloom, M.W. Morgan (Eds.).
20. Lahdes K, Huupponen R, Kaila T, et al. Systemic absorption of ocular scopolamine in patients. J Ocular Pharm 1990, 6:61-66.
21. Lahdes K, Kaila T, Huupponen R, et al. Systemic absorption of topically applied ocular atropine. Clin Pharmacol Ther 1988, 44:310-314.
22. Larkin KM, Charap A, Cheetham JK, Frank J Ideal concentration of tropicamide with hydroxyamphetamine 1% for routine pupillary dilation. Ann Ophthalmol 1989, 21:340-344.
23. Lovasik JV Pharmacokinetics of topically applied cyclopentolate HCl and tropicamide. Am J Optom Physiol Opt 1986, 63:787-803.
24. Lovasik JV, Kergoat H Time course of cycloplegia induced by a new phenylephrine-tropicamide combination drug. Optom Vis Sci 1990, 67:352-358.
25. Luft WA, Ming Y, Stell WK Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. Invest Ophthalmol Vis Sci 2003, 44:1330-1338.
26. Luu CD, Am Lau, Koh AH, Tan D Multifocal electroretinogram in children on atropine treatment for myopia. Br J Ophthalmol 2005, 89:151-153.
27. Manny RE, Fern KD, Zervas HJ, et al. 1% Cyclopentolate hydrochloride: another look at the time course of cycloplegia using an objective measure of the accommodative response. Optom Vis Sci 1993, 70:651-665.
28. Manny RE, Hussein M, Scheiman M, et al. Tropicamide (1%): an effective cycloplegic agent for myopic children. Invest Ophthalmol Vis Sci 2001, 42:1728-1735.
29. Merrill DL, Goldberg B, Zavell S Bis-Tropicamide, a new parasympatholytic. Curr Ther Res 1960, 2:43-50.
30. Milder B, Riffenburgh RS An evaluation of Cyclogyl (compound 75 GT). Am J Ophthalmol 1953, 36:1724-1726.
31. Mutti DO, Zadnik K, Egashira S, et al. The effect of cycloplegia on measurement of the ocular components. Invest Ophthalmol Vis Sci 1994, 35:515-527.
32. Patel KH, Javitt JC, Tielsch JM, et al. Incidence of acute angle-closure glaucoma after pharmacologic mydriasis. Am J Ophthalmol 1995, 120:709-717.
33. Pollack SL, Hunt JS, Polse KA Dose-response effects of tropic-amide HCl. Am J Optom Physiol Opt 1981, 58:361-366.
34. Priestly BS, Medine MM, Phillips CC Cyclomydril: a new mydriatic agent. Am J Ophthalmol 1960, 49:1033-1034.
35. Repka MX, Ray JM The efficacy of optical and pharmacological penalization. Ophthalmology 1993, 100:769-774.
36. Sampson WG Role of cycloplegia in the management of functional myopia. Ophthalmology 1979, 86:695-697.
37. Siatkowski RM, Cotter S, Miller JM, et al. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol 2004, 122:1667-1674.
38. Siderov J, Chuang SM-L, Ian K, et al. Effect of proparacaine on tropicamide-induced mydriasis. Optom Vis Sci 1997, 74:1039-1043.
39. Tan DT, Lam DS, Chua WH, et al. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology 2005, 112:84-91.
40. Van Herick WV, Shaffer RN, Schwartz A Estimation of the width of the angle of the anterior chamber. Incidence and significance of the narrow angle. Am J Ophthalmol 1969, 68:626-629.
41. Von Noorden GK, Milam JB Penalization in the treatment of amblyopia. Am J Ophthalmol 1979, 88:511-518.
42. Wolf AV, Hodge HC Effects of atropine sulfate, methylatropine nitrate (Metropine) and homatropine hydrobromide on adult human eyes. Arch Ophthalmol 1946, 36:293-301.
43. Wolfs RCW, Grobbee DE, Hofman A, de Jong PTVM Risk of acute angle-closure glaucoma after diagnostic mydriasis in nonselected subjects: the Rotterdam Study. Invest Ophthalmol Vis Sci 1997, 38:2683-2687.
44. Yolton DP, Kandel JS, Yolton RL Diagnostic pharmaceutical agents: side effects encountered in a study of 15,000 applications. J Am Optom Assoc 1980, 51:113-117.
45. Zinn KM Chapters 1 and 2. The pupil 1972, Charles C Thomas, Springfield, IL.